Skip to main content
Signal8

CODEXIS, INC. (CDXS)

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.

Sector: Industrial Organic Chemicals

Industry: Biotechnology

Codexis, Inc. logo

Codexis, Inc.

NASDAQ:CDXSHealthcare
-2.29%$1.28
AH Close$1.31+2.34%vs close
Mkt Cap$140.17M
Float105.4M
O/S109.51M
Inst Own58.4%
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$140.17M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership58.45%

based on 109.51M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateApr 22, 2010
Shares Outstanding109.51M
Float105.40M
Company Overview

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions.

Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening.

The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.

Leadership

Alison Moore, Ph.D.

Christos Richards

Cynthia Collins

David V. Smith

Employees

146

Country

US

Sector

Healthcare

Website

codexis.com

Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
No price targets available
Ratings Distribution
BUY
9
HOLD
5
SELL
0
TOTAL14
Insider Trading
InsiderTypeShares
Erbez Georgia profile photoErbez GeorgiaSale6.3K
MOORE ALISON profile photoMOORE ALISONSale6.3K
PARKER H STEWART profile photoPARKER H STEWARTGrant/Award66.3K
De Vre Raymond profile photoDe Vre RaymondGrant/Award66.3K
DILLY STEPHEN GEORGE profile photoDILLY STEPHEN GEORGEGrant/Award66.3K
Martinborough Esther profile photoMartinborough EstherGrant/Award66.3K
Shareholders
58.4%
Institutional
(144)
2.1%
Insiderⓘ
(13)
0.0%
5%+ Owners
(0)
39.5%
Unattributed (incl. retail)ⓘ
Institutional58.4%
Insider2.1%
Unattributed (incl. retail)39.5%
Sources: 13F, Form 4, 13D/13GO/S: 109.5M · as of 6 Aug 2026 · SEC cover page
Insiders & Institutional Holders
52-Week Range
$0.9583$2.98
$1.28(16th percentile)
Volume
Average Daily Volume824.13K
542.51K today vs 824.13K avg(-34%)

30d Avg

824.13K

60d Avg

852.88K

90d Avg

939.72K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...